Nutlin-3, the small-molecule inhibitor of MDM2, promotes senescence and radiosensitises laryngeal carcinoma cells harbouring wild-type p53

Arya AK, A El-Fert, T Devling, RM Eccles, MA Aslam, CARLOS RUBBI, N Vlatkovic, J Fenwick, BH Lloyd, DR Sibson, TM Jones, MT Boyd

Research output: Contribution to journalArticle (journal)peer-review

52 Citations (Scopus)

Abstract

Primary radiotherapy (RT) is a mainstay of treatment for laryngeal squamous cell carcinoma (LSCC). Although the cure rates for early (T1) vocal cord tumours are high, RT proves ineffective in up to a third of T3 carcinomas. Moreover, RT is associated with debilitating early- and late-treatment-related toxicity, thus finding means to de-escalate therapy, while retaining/augmenting therapeutic effectiveness, is highly desirable. p53 is a key mediator of radiation responses; we therefore investigated whether Nutlin-3, a small-molecule inhibitor of MDM2 (mouse double minute 2; an essential negative regulator of p53), might radiosensitise LSCC cells.
Original languageEnglish
Pages (from-to)186-195
JournalBritish Journal of Cancer
Volume103
DOIs
Publication statusPublished - 29 Jun 2010

Fingerprint

Dive into the research topics of 'Nutlin-3, the small-molecule inhibitor of MDM2, promotes senescence and radiosensitises laryngeal carcinoma cells harbouring wild-type p53'. Together they form a unique fingerprint.

Cite this